人血清白蛋白
依托泊苷
内化
化学
白蛋白
硼酸
药理学
细胞毒性
肺癌
医学
生物化学
化疗
组合化学
外科
细胞
体外
肿瘤科
作者
Mayada M. Elgohary,Maged W. Helmy,Sana Mohamed Mortada,Ahmed O. Elzoghby
出处
期刊:Nanomedicine
[Future Medicine]
日期:2018-09-01
卷期号:13 (17): 2221-2224
被引量:44
标识
DOI:10.2217/nnm-2018-0097
摘要
Aim: A Nano-in-Nano approach was exploited to facilitate incorporation of the chemotherapeutic drug etoposide (ETP) as nanosuspension, synergistically with berberine (BER) into hydrophilic albumin nanoparticles (HSA NPs).Methods: For maximal tumor targeting, HSA was modified with mannose and phenyl-boronic acid. Furthermore, different crosslinkers were investigated for sustained release of water soluble BER from HSA NPs. Results: The elaborated dual-targeted HSA NPs (216.2 nm) were spherical with high BER and ETP entrapment efficiency (69.5 and 87.6%, respectively) and loading (10.52 and 14.04%, respectively). The NPs exhibited sequential release pattern for both ETP and BER (51.55 and 34.33% over 72 h, respectively). Phenyl-boronic acid/mannose-HSA NPs demonstrated powerful cytotoxicity against A549 lung cancer cells (IC50: 12.4 μg/ml) correlated to enhanced cellular internalization. Dual-targeted NPs displayed 9.77-fold higher caspase-3 level and 3.5-fold lower VEGF level than positive control mice. Conclusion: Dual-targeted Nano-in-Nano albumin carriers could be beneficial for parenteral ETP/BER delivery to lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI